Life Therapeutics (ASX: LFE) announced today that the company has started an early-stage project to develop a specialty immune globulin for influenza. This is a multi-year program to immunize selected donors with the flu vaccine and collect their hyperimmune blood plasma for use in a therapeutic drug to combat infection caused by the influenza virus.
